Vaccine Therapy in Treating Patients With Multiple Myeloma
Phase 2 Completed
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances
Phase 2 Completed
70 enrolled
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
Phase 2 Withdrawn
Experimental Bone Marrow Transplant Protocol
Phase 2 Completed
14 enrolled
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
Phase 2 Completed
50 enrolled 12 charts
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
Phase 2 Unknown
30 enrolled
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
Phase 2 Unknown
10 enrolled
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Phase 2 Unknown
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
Phase 2 Unknown
52 enrolled
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
Phase 2 Unknown
30 enrolled
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase 2 Unknown
35 enrolled
Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma
Phase 2 Completed
30 enrolled
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
Phase 2 Unknown
60 enrolled
Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase 2 Completed
35 enrolled
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
Phase 2 Unknown
80 enrolled
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma
Phase 2 Unknown
100 enrolled
Combination Chemotherapy in Treating Patients With Multiple Myeloma
Phase 2 Completed
Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 2 Withdrawn
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
Phase 2 Withdrawn
Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma
Phase 2 Completed
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
Phase 2 Completed
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
Phase 2 Completed
Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 2 Completed
Interleukin-12 in Treating Patients With Multiple Myeloma
Phase 2 Completed
40 enrolled
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
Phase 2 Completed
40 enrolled
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis
Phase 2 Completed
75 enrolled
4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
Phase 2 Completed
45 enrolled
Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer
Phase 2 Completed
82 enrolled
Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment
Phase 2 Completed
48 enrolled
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
Phase 2 Unknown
50 enrolled
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
Phase 2 Unknown
43 enrolled
Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis
Phase 2 Completed
25 enrolled